WASHINGTON -- Semaglutide (Wegovy) improved liver inflammation and fibrosis in patients with metabolic dysfunction-associated ...

Novo Nordisk’s oral semaglutide 25 mg achieved up to 16.6% weight loss in a landmark study, rivaling injectable Wegovy. The ...

Emcure Pharma becomes the first Indian company to hold exclusive rights to distribute and commercialise Poviztra, a ...

Injectable weight-loss drugs can reduce the risk of serious cardiovascular events for people with type 2 diabetes.

Novo Nordisk today presented data at the 76th annual American Association for the Study of Liver Diseases (AASLD) meeting, ...

Novo Nordisk India partners with Emcure Pharma to distribute and market Poviztra (semaglutide) nationwide, expanding access ...

Oral semaglutide improved glycemic parameters and cardiovascular risk factors for adults with overweight or obesity, with ...

This article was reviewed by Darragh O’Carroll, MD. Oral vs. Injectable Semaglutide: Effectiveness & Side Effects Key ...

Adults with obesity lose more weight with semaglutide than with placebo (a sham medication). However, the risk of unwanted events is probably higher than with placebo after 24 months. Semaglutide ...

A drug most often prescribed for diabetes and obesity might soon be prescribed to curb one of the world’s hardest to quit ...

The Indian subsidiary of Danish pharma major Novo Nordisk has partnered with Pune-based Emcure Pharma to expand the reach of ...